Related Experiment Video

Updated: Jul 8, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.6K

Corrigendum: Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an

Takashi Shimizu1,2, Eisuke Inoue3, Ryotaro Ohkuma1,4

  • 1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.

Frontiers in Immunology
|December 20, 2023
PubMed

Insights

This study corrects a previously published article DOI. The correction ensures accurate citation and retrieval of scientific information for researchers.

Area of Science:

  • This study falls under the field of scientific publishing and research integrity.

Context:

  • A previous article DOI was published with an error.
  • Accurate citation is crucial for scientific reproducibility and tracking research impact.

Purpose:

  • To provide the correct article DOI for the publication.
  • To ensure proper referencing and accessibility of the research.

Summary:

  • The abstract provides a correction to the article's Digital Object Identifier (DOI).
  • This ensures that the scientific community can correctly access and cite the research.

Impact:

  • Facilitates accurate citation and retrieval of the scientific article.
  • Upholds the integrity of scientific records and scholarly communication.
Keywords:
PD-1 inhibitorsadvanced non-small cell lung cancerbiomarkerindividual patient data meta-analysissoluble PD-L1

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K